ICML 2023 | Genomic evolution & resistance to pirtobrutinib in covalent BTK inhibitor pre-treated CLL
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, discusses the results of an analysis conducted on a subgroup of patients with chronic lymphocytic leukemia (CLL) who progressed on pirtobrutinib after being previously treated with a covalent BTK inhibitor. Dr Patel highlights novel mutations observed in these patients, and further explains how these findings may provide valuable information on the underlying mechanisms of resistance to pirtobrutinib. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant or advisory role: Abbvie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Caribou Biosciences, Celgene, Epizyme, Genentech/Roche, Kite, Loxo Oncology, MEI Pharma, Morphosys, Pharmacyclics/Janssen, TG Therapeutics, Trillium Therapeutics/Pfizer, Xencor
Research funding: Adaptive Biotechnologies, Aptevo Therapeutics, AstraZeneca, Bristol Myers Squibb, CRISPR Therapeutics, Celgene, Curis, Inc, Epizyme, Fate Therapeutics, Genentech/Roche, Kite, Loxo Oncology, MEI Pharma, Nurix, Pharmacyclics/Janssen, Sunesis, Pharmaceuticals, Trillium Therapeutics/Pfizer, Velos Bio, Xencor
